Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Mesoblast Limited (MESO) vs Quantum Computing Inc (QUBT) Price & Performance

Mesoblast LimitedTrade
Quantum Computing IncTrade

Price performance (Past 24H)

Key statistics

Mesoblast Limited vs Quantum Computing Inc — how do they compare? Mesoblast Limited trades at $16.74 (market cap $2.20B), while Quantum Computing Inc trades at $8.92 (market cap $2.03B). The key difference: Mesoblast Limited and Quantum Computing Inc are close in size by market cap, and Mesoblast Limited is trading nearer its 52-week high, Quantum Computing Inc nearer its low. Which is the better fit depends on your goals.

MESOQUBT
Market Cap
$2.20B$2.03B
Sector
TechnologyTechnology
52-Week High
$20.96$24.62
52-Week Low
$12.88$6.31
Enterprise Value
$2.20B$1.09B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Mesoblast Limited

MESO trades at $16.78, up 0.6% with a bullish technical signal from moving averages. The company shows strong revenue growth with Ryoncil generating $115M in its first year, but remains unprofitable with a -144% net margin. Recent milestones include Phase 3 trial completion for chronic back pain and BLA filing for heart failure treatment, indicating pipeline progress.

Investment outlook balances promising commercial traction against significant financial losses. The stock offers growth potential from expanding indications but carries high risk due to negative earnings and dependence on regulatory approvals. Analyst consensus leans bullish with 45% buy ratings, though profitability remains the key challenge.

Quantum Computing Inc

Quantum Computing Inc. (QUBT) trades at $8.92, down slightly by 0.11% on the day, with a bearish technical signal. The company is in a high-growth but pre-profit phase, reporting Q2 2026 revenue of $5.6 million (MarketBeat, 2026-08-10), a significant increase, but with persistent net losses. Analyst sentiment is positive with a 75% buy rating and a consensus price target of $18.50, indicating substantial upside potential from current levels.

The outlook for QUBT is speculative, offering high growth potential in quantum computing and photonics, supported by strong institutional interest and revenue expansion. Key risks include steep valuation (P/S of 189.05), ongoing losses, high cash burn, and competitive pressures in the emerging quantum sector, requiring careful risk assessment by investors.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Mesoblast Limited

Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.

Read more on MESO

About Quantum Computing Inc

Quantum Computing Inc. is a company focused on providing accessible quantum computing and quantum-enhanced software solutions for complex problems. The company's technology is designed to run on both classical and quantum hardware, enabling businesses to explore the power of quantum computing today for applications in finance, drug discovery, and logistics. QUBT offers a platform that makes quantum algorithms and software available through the cloud, aiming to democratize access to this advanced computing paradigm.

Read more on QUBT